-
Oculis’ OCS-01 Achieves Primary Efficacy Endpoint in Phase III DIAMOND Trial for DME
•
US-based Oculis Holding AG (NASDAQ: OCS) has announced positive top-line results from Stage 1 of its Phase III DIAMOND trial for the eye drop drug candidate OCS-01, which is being assessed as a treatment for diabetic macular edema (DME). The trial data indicate that the drug achieved its primary efficacy…
-
Nona Biosciences and ModeX Therapeutics Partner to Develop Polyspecific Antibodies
•
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), which operates across the Netherlands, the United States, and China, has announced a strategic partnership with OPKO Health’s subsidiary, ModeX Therapeutics. The collaboration will fully leverage Nona Bio’s Harbor Mice whole human transgenic mouse platform technology for the development…
-
NHSA Proposes Draft to Enhance Basic Medical Insurance Payment Management for Consumables
•
The National Healthcare Security Administration (NHSA) has issued a Notice seeking public feedback on draft proposals aimed at “Improving the Basic Medical Insurance Payment Management of Medical Consumables.” The proposals address the rapid development of the medical consumables industry in China and its increasing share of health expenditure, making it…
-
SinoMab BioScience’s SM17 IND Accepted by NMPA for Potential Global First-in-Class Monoclonal Antibody
•
Hong Kong-based biotech SinoMab BioScience Ltd (HKG: 3681) has announced that the National Medical Products Administration (NMPA) has accepted for review an investigational new drug (IND) filing for SM17, a potential global first-in-class monoclonal antibody. Developed in-house by SinoMab, SM17 is the world’s first humanized IgG4-κ monoclonal antibody targeting IL-17RB,…
-
China Aims to Establish Basic Elderly Care System by 2025, Outlines Comprehensive Plan
•
The General Office of the CPC Central Committee and General Office of the State Council have released an “Opinions” paper titled “Promoting the Construction of the Basic Elderly Care Service System.” The document outlines a target to establish a fundamentally sound elderly care system by the end of 2025, with…
-
JW Therapeutics Secures Supply Agreement with Juno to Advance CAR-T Therapy Commercialization
•
China-based JW Therapeutics (HKG: 2126) has announced a carrier supply agreement with its shareholder Juno, aimed at supporting the continuous commercialization and further clinical development of its chimeric antigen receptor (CAR) T cell therapy, Carteyva (relmacabtagene autoleucel injection). Financial Terms and ProjectionsThe agreement outlines that from the effective date of…
-
HighTide Therapeutics’ HTD1801 Meets Primary and Secondary Endpoints in Type 2 Diabetes Phase II Study
•
China-based HighTide Therapeutics Inc. (HKG: 2511) has announced that its Phase II study for the drug candidate HTD1801 (berberine ursodeoxycholate, BUDCA) as a treatment for type 2 diabetes (T2DM) has achieved its primary endpoint and several important secondary endpoints. The study demonstrated that treatment with HTD1801 resulted in a superior…
-
GenScript Biotech’s Legend Biotech Secures Private Placement with Hillhouse Investment
•
China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has revealed that its subsidiary, Legend Biotech Corporation (NASDAQ: LEGN), is set to conduct a private placement of 692,800 shares at USD 32 per share to LGN Holdings Ltd, a company solely managed by Hillhouse Investment Management, Ltd. This transaction…
-
Zhejiang Conba Pharmaceutical’s Inhalable Pirfenidone for IPF Clears for Chinese Clinical Trials
•
Zhejiang Conba Pharmaceutical Co., Ltd (SHA: 600572) has announced that its modified version of US firm Marnac’s pirfenidone, in the form of an inhalable solution, has been approved for clinical trials in China. The drug is aimed at treating idiopathic pulmonary fibrosis (IPF), a progressive lung disease characterized by diffuse…
-
Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for Two Autoimmune Disease Drug Candidates
•
China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has separately announced clinical trial approvals from the National Medical Product Administration (NMPA) for two of its drug candidates, SHR-1654 and SHR-2001. These molecules are set for assessment as potential treatments for rheumatoid arthritis and systemic lupus erythematosus, respectively. SHR-1654: A Novel Treatment for…
-
Sino-US Laekna Receives FDA Clearance for LAE102 Clinical Trial in NSCLC
•
Sino-US Laekna has announced that it has received clinical trial clearance from the US Food and Drug Administration (FDA) for its LAE102 antibody. The drug is set to be assessed as a potential treatment for non-small cell lung cancer (NSCLC). This achievement marks LAE102 as Laekna’s first internally-discovered drug candidate…
-
Beijing Hospitals to Pilot DRG-VBP Reforms for Medical Consumables Procurement
•
The Beijing Municipal Medical Insurance Bureau has released a notification indicating that six hospitals in the city are set to carry out a special tender that links diagnosis-related group (DRG) reforms with volume-based procurement (VBP) for medical consumables in the sports medicine, neurointervention, and electrophysiology fields. The participating hospitals include…
-
Lundbeck A/S Reports Record Quarterly Revenue in Q1 2023 with 11% YOY Increase
•
Denmark-based pharmaceutical company Lundbeck A/S (OTCMKTS: HLUBF) has released its financial report for the first quarter of 2023, highlighting an 11% year-on-year (YOY) increase in global sales revenues in constant exchange rate terms, reaching DKK 5.044 billion (USD 731.2 million). This figure marks the highest quarterly revenue in the company’s…
-
Cabaletta Bio’s CABA-201 Clears FDA for Phase I/II Study in Idiopathic Inflammatory Myopathy
•
US-based Cabaletta Bio, Inc. (NASDAQ: CABA) has announced that the US Food and Drug Administration (FDA) has cleared the company’s second Investigational New Drug (IND) application for CABA-201, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy. The clearance is for a Phase I/II study in patients with active idiopathic…
-
MicroPort Scientific Plans IPO for Subsidiary MicroPort CRM on Hong Kong Stock Exchange
•
Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has announced its intention to spin off its France-based subsidiary, MicroPort Cardiac Rhythm Management Limited (MicroPort CRM), to pursue an initial public offering (IPO) on the Hong Kong Stock Exchange. This move has been confirmed by the bourse, and MicroPort expects…
-
Mustang Bio, Inc. Enters Strategic Partnership with uBriGene for Cell and Gene Therapy
•
US-based Mustang Bio, Inc. has announced a strategic partnership with uBriGene (Boston) Biosciences Inc., the US subsidiary of China-based uBriGene, a leading cell and gene therapy contract development and manufacturing organization (CDMO). This deal will result in the sale of Mustang’s development, manufacturing, and analytical testing facility in Worcester, Massachusetts…
-
Beijing Sun-Novo Secures Exclusive Rights to Kaneka’s Skin Patch Drugs in Licensing Deal
•
China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has announced a licensing agreement with Japanese firm Kaneka Corporation, securing exclusive patent rights and technical know-how for two skin patch drugs, SN001 and SN002. The agreement covers the Chinese mainland, Hong Kong, and Macao markets, expanding the reach of these…
-
International Vaccine Institute and Nankai University Establish Joint Research Center for Vaccine Advancements
•
The International Vaccine Institute (IVI), a non-profit international organization initiated by the United Nations Development Programme (UNDP), has entered into a partnership with China’s Nankai University to establish the “International Vaccine Research Institute Nankai Joint Research Center”. This collaboration aims to enhance global health initiatives through joint efforts in vaccine…
-
MicroPort MedBot Receives NMPA Approval for Mona Lisa Prostate Puncture Robot System
•
Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for the ISR’obot Mona Lisa prostate puncture robot positioning system. This product is a result of a joint venture between MicroPort MedBot and Biobot Surgical Pte. Ltd,…
-
Liaoning-Led Alliance Launches Volume-Based Procurement Tender for Hernia and Dural Patches
•
A 12-strong provincial procurement alliance, spearheaded by Liaoning province, has announced the initiation of a volume-based procurement (VBP) tender round focused on hernia patches, including inguinal and abdominal wall hernia patches, as well as dural (spinal) membrane patches. The alliance includes participants such as Shanxi, Inner Mongolia Autonomous Region, Jilin,…
